Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 23, Issue SUPPL. 7, 2012, Pages

  Colombo, N ^a,b   Carinelli, S ^a   Colombo, A ^c   Marini, C ^d   Rollo, D ^a   Sessa, C ^d,e  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

^c A MANZONI HOSPITAL   (Italy)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOOXYGENASE 2; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; GEMCITABINE; NAVELBINE; PACLITAXEL; TOPOTECAN; VASCULOTROPIN;

ADENOCARCINOMA; ADVANCED CANCER; ARTICLE; CANCER ADJUVANT THERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FOLLOW UP; HIGH RISK PATIENT; HUMAN; HYSTERECTOMY; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; METASTASIS; MOLECULAR PATHOLOGY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; SURVIVAL TIME; TREATMENT PLANNING; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA;

EID: 84866626878     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mds268     Document Type: Article

References (30)

1. Ferlay J, Shin HR, Bray F et al. GLOBOCAN 2008, cancer incidence and mortality Worldwide: IARC CancerBase No. 10. Lyon, France: International Agency for Research on Cancer [on-line] 2010; http://globocan.iarc.fr
2. Arbyn M, Castellsague X, de Sanjose S et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22: 2675-2686.
3. Mark AK. Preventing cancer with vaccines: progress in the global control of cancer. Cancer Prev Res 2012; 5: 24-29.
4. Sankaranarayanan R, Nene BM, Shastri SS et al. HPV screening for cervical cancer in rural india. N Engl J Med 2009; 360: 1385-1394.
5. Féderation Internationale de Gynécologie et d'Obstétrique FIGO Committee on Gynecology Oncology. Revised FIGO staging for carcinoma of the vulva, cervix and endometrium. Int J Gynecol Obstet 2009; 105: 103-104.
6. Wagenaar HC, Trimbos JB, Postema S et al. Tumor diameter and volume assessed by magnetic resonance imaging in the prediction of outcome of invasive cervical cancer. Gynecol Oncol 2001; 82: 474-482.
7. Patel CN, Nazir SA, Khan Z et al. 18F-FDG PET/CT of cervical carcinoma. AJR Am J Roentgenol 2011; 196: 1225-1233.
8. Brockbank E, Kokka F, Bryant A et al. Pre-treatment surgical para-aortic lymph node assessment in locally advanced cervical cancer. Cochrane Database Syst Rev 2011; 4: CD008217.
9. Kim SM, Choi HS, Byun JS. Overall 5-year survival rate and prognostic factors in patients with stage IB and IIA cervical cancer treated by radical hysterectomy and pelvic lymph node dissection. Int J Gynecol Cancer 2000; 10: 305-312.
10. Landoni F, Maneo A, Colombo A et al. Randomised study of radical surgery versus radiotherapy for stage IB-IIA cervical cancer. Lancet 1997; 350: 535-540.
11. Schneider A, Erdemoglu E, Chiantera V et al. Clinical recommendation radical trachelectomy for fertility preservation in patients with early stage cervical cancer. Int J Gynecol Cancer 2012; 22(4): 659-666.
12. Maneo A, Sideri M, Scambia G et al. Simple conization and lymphadenectomy for the conservative treatment of stage IB1 cervical cancer. An Italian experience Gynecol Oncol. Gynecol Oncol 2011; 123(3): 557-560.
13. Barillot I, Horiot JC, Pigneux J et al. Carcinoma of the intact uterine cervix treated with radiotherapy alone: a French cooperative study: update and multivariate analysis of prognostics factors. Int J Radiat Oncol Biol Phis 1997; 38: 969-978.
14. Perez CA, Grigsby PW, Chao KS et al. Tumor size, irradiation dose, and longterm outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 1998; 41: 307-317.
15. Whitney CW, Sause W, Bundy BN et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIBIVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999; 17: 1339-1348.
16. Rose PG, Bundy BN, Watkins EB et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999; 340: 1144-1153.
17. Morris M, Eifel PJ, Lu J et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340: 1137-1143.
18. Keys HM, Bundy BN, Stehman FB et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999; 340: 1154-1161.
19. Peters WA, III, Liu PY, Barrett RJ, II et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-1613.
20. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26: 5802-5812.
21. Pearcey R, Brundage M, Drouin P. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002; 20: 966-972.
22. Dueñas-González A, Zarbá JJ, Patel F et al. A phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011; 29: 1678-1685.
23. Neoadjuvant Chemotherapy for Cervical Cancer Meta-analysis Collaboration (NACCCMA). Neoadjuvant chemotherapy for locally advanced cervix cancer. Cochrane Database Syst Rev 2004; 2: CD001774.
24. Rotman M, Sedlis A, Piedmonte MR et al. A phase III randomized trial of postoperative pelvic irradiation in Stage IB cervical carcinoma with poor prognostic features: follow-up of a Gynecologic Oncology Group study. Int J Radiat Oncol Biol Phys 2006; 65: 169-176.
25. Tao X, Hu W, Ramirez PT et al. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol 2008; 110: 67-71.
26. Pectasides D, Kamposioras K, Papaxoinis G et al. Chemotherapy for recurrent cervical cancer. Cancer Treat Rev 2008; 34: 603-613.
27. Long HJ, Bundy BN, Grendys EC et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 4626-4633.
28. Monk BJ, Sill MW, McMeekin DS et al. Phase III trial of four cisplatincontaining doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 4649-4655.
29. Moore KN, Herzog TJ, Lewin S et al. A comparison of cisplatin/paclitaxel and carboplatin/paclitaxel in stage IVB, recurrent or persistent cervical cancer. Gynecol Oncol 2007; 105: 299-303.
30. Kitagawa R, Katsumata N, Shibata T et al. A randomized phase III trial of paclitaxel plus carboplatin (TC) versus paclitaxel plus cisplatin (TP) in stage IVb, persistent or recurrent cervical cancer: Japan Clinical Oncology Group Study (JCO GO505). J Clin Oncol 2012; 30(155): Abstr. 5006.